Sherief Abd-Elsalam
Tanta, Egypt
Location status: Recruiting
NCT Number: NCT04766177
Role of bumetanide in Autism
Interested in participating?
Request Info3 year–12 year
All sexes
Interventional
Phase 3
Tanta, Egypt
Location status: Recruiting
Role of Bumetanide in Treatment of Autism spectrum disorder in children
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
bumetanide 0.5 mg twice daily
Other names: burinex
placebo tablets twice daily
Other names: Placebo treatment
Time frame: 6 months
the patients with improved CARS score
Contact information is provided by the study sponsor or research team.
Sherief Abd-Elsalam
Other
Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06081348
22Q11 Deletion, 22q11 Deletion Syndrome
Calgary, Alberta, Canada
View Trial DetailsNCT07476937
Autism, Autism Spectrum Disorder
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT07708246
Autism, Autism Spectrum Disorder
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07500363
Autism, Autism Spectrum Disorder
Sacramento, California, United States
View Trial Details